Aragon Pharmaceuticals Receives $22,000,000 Series B Financing
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=f63a0b96-de96-4815-837a-947ab4dea4a7&Preview=1 -
Date
4/23/2010 -
Company Name
Aragon Pharmaceuticals -
Mailing Address
4215 Sorrento Valley Blvd. San Diego, CA 92121 -
Company Description
Aragon Pharmaceuticals is a San Diego based biopharmaceutical company focused on developing a pipeline of new anti-endocrine therapies targeting the biology of hormone resistant cancers. -
Website
http://www.aragonpharmaceuticals.com -
Transaction Type
Venture Equity -
Transaction Amount
$22,000,000 -
Transaction Round
Series B -
Proceeds Purposes
This financing will allow us to advance ARN-509 into clinical trials and continue the discovery and development of selective androgen receptor degraders and selective estrogen receptor degraders for the treatment of prostate and breast cancers. -
M&A Terms
-
Venture Investor
Aisling Capital -
Venture Investor
OrbiMed -
Venture Investor
The Column Group
